The UK’s National Aspergillosis Centre Approach to the Management of Chronic Pulmonary Aspergillosis
February 26 2018
Evidence-based guidance for management of CPA is currently limited by the small number of randomized controlled trials investigating different antifungal regimes. Dr Firas Maghrabi and Professor David Denning at have recently published an article on the approach used the National Aspergillosis Centre (Manchester, UK) to coincide with the centre being awarded Diamond Status as an ECMM Excellence Centre.
Distinct radiological appearance of cerebral aspergillosis in immunocompetent patients
February 22 2018
A high index of suspicion for CNS aspergillosis should be maintained in the immunocompetent patient with a brain mass, especially in the presence of concomitant sinus disease. These lesions generally appear hypointense on T2-weighted MRI scans and CT scans, but generally isointense on T1-weighted MRI scans. Bright homogeneous enhancement is more common than ring enhancement in this group.
New CME activity on recognising azole-resistant aspergillosis launched by the CDC (via Medscape)
February 13 2018
A new CME activity (1 credit) published by the CDC aims to teach clinicians in the US about the causes and clinical patterns of azole resistance and availability of resistance testing.
New (1-3)-β-D-Glucan assay for Pneumocystis pneumonia evaluated
February 09 2018
Lewis White and colleagues in the UK carried out a retrospective study to evaluate the new Dynamiker® Fungus BDG assay. When used to detect Pneumocystis jirovecii pneumonia (PCP), the assay showed a sensitivity of 87% and specificity of 70%.
8th Advances Against Aspergillosis meeting held in Lisbon
February 07 2018
The LIFE team were delighted to attend the AAA 2018 in Lisbon last week, and will be posting video presentations and abstracts on our websites shortly.